Lepu Biopharma Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Feb 10, 2022 - (ACN Newswire) - The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange"). Lepu Biopharma plans to offer 126,876,000H shares...

Related Keywords

Australia ,Japan ,Shanghai ,China ,New Zealand ,India ,Hong Kong ,Israel ,Beijing ,Chile ,Colombia ,Indonesia ,South Korea ,Huatai ,Jiangxi ,Lepu Biopharma ,Pu Zhongjie ,Lepu Biophamra ,Morgan Stanley Asia ,Huatai Financial Holdings Hong Kong ,Haitong International Securities Company ,International Offer ,China International Capital Corporation Hong Kong Securities ,Property Promotes The Sustainable Development Of Drugs ,Capital Ltd ,Lepu Biopharma Co Ltd ,China Galaxy International Securities Hong Kong Co ,Technology Platforms Construction ,European Union ,Innovative Drugs Development ,Core Technology Platforms To Buttress Products ,Morgan Stanley Co ,Tiger Brokers Hk Global ,Main Board ,Stock Exchange ,Hong Kong Limited ,Kong Stock ,Over Allotment Option ,International Offer Shares ,Hong Kong Offer Shares ,Hong Kong Public Offering ,Hong Kong Stock Exchange ,Morgan Stanley Asia Limited ,Joint Sponsors ,Joint Global ,Morgan Stanley ,Haitong International Securities Company Limited ,Huatai Financial Holdings ,China Galaxy International Securities ,Valuable Capital ,Tiger Brokers ,Global Limited ,Joint Lead ,Latest Practicable Date ,Encouraging Clinical Trial Results ,Technology Platforms ,Buttress Products ,Property Promotes ,Sustainable Development ,Commercialization Layout ,Mainland China ,Shanghai Biotech Park ,Executive Director ,